Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: Potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway

Masako Saka, Koji Obata, Sahoko Ichihara, Xian Wu Cheng, Hirotaka Kimata, Akiko Noda, Hideo Izawa, Kohzo Nagata, Mitsuhiro Yokota

研究成果: Article

25 引用 (Scopus)

抄録

1. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) manifest pleiotropic effects that may contribute to their therapeutic efficacy. However, the mechanism of the beneficial action of statins on cardiac hypertrophy and fibrosis remains unclear. We have now investigated this action of pitavastatin in Dahl salt-sensitive (DS) rats. 2. The DS rats progressively develop marked hypertension when fed a diet containing 8% NaCl from 7 weeks of age. These animals exhibited pronounced cardiac hypertrophy and fibrosis, as well as upregulation of fetal-type cardiac gene expression at 12 weeks of age, compared with DS rats fed a diet containing 0.3% NaCl. The abundance of mRNAs for collagen types I and III, angiotensin-converting enzyme, transforming growth factor-β1 and connective tissue growth factor was also increased in the heart of rats on the high-salt diet. 3. Treatment of rats on the high-salt diet with a non-antihypertensive dose of pitavastatin (0.3 or 1 mg/kg per day) from 7 to 12 weeks of age attenuated the development of cardiac hypertrophy and fibrosis, as well as inhibiting the upregulation of cardiac gene expression. Pitavastatin also blocked the translocation of RhoA to the membrane fraction of the left ventricle and RhoA activation, as well as the phosphorylation of the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK)-1 and ERK-2 and an increase in the DNA binding activity of serum response factor (SRF) in the heart induced by the high-salt diet. 4. These findings suggest that the effects of pitavastatin on load-induced cardiac hypertrophy and fibrosis are independent of its cholesterol-lowering action and may be mediated, at least in part, through inhibition of RhoA-ERK-SRF signalling.

元の言語English
ページ(範囲)1164-1171
ページ数8
ジャーナルClinical and Experimental Pharmacology and Physiology
33
発行部数12
DOI
出版物ステータスPublished - 01-12-2006

Fingerprint

Serum Response Factor
Extracellular Signal-Regulated MAP Kinases
Hypertrophy
Cardiomegaly
Inbred Dahl Rats
Fibrosis
Diet
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Salts
Up-Regulation
Connective Tissue Growth Factor
Gene Expression
Collagen Type III
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Transforming Growth Factors
Peptidyl-Dipeptidase A
Collagen Type I
Mitogen-Activated Protein Kinases
Heart Ventricles

All Science Journal Classification (ASJC) codes

  • Physiology
  • Pharmacology
  • Physiology (medical)

これを引用

Saka, Masako ; Obata, Koji ; Ichihara, Sahoko ; Cheng, Xian Wu ; Kimata, Hirotaka ; Noda, Akiko ; Izawa, Hideo ; Nagata, Kohzo ; Yokota, Mitsuhiro. / Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin : Potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway. :: Clinical and Experimental Pharmacology and Physiology. 2006 ; 巻 33, 番号 12. pp. 1164-1171.
@article{d923c9f948d847ed8ede4bb7589a2916,
title = "Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: Potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway",
abstract = "1. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) manifest pleiotropic effects that may contribute to their therapeutic efficacy. However, the mechanism of the beneficial action of statins on cardiac hypertrophy and fibrosis remains unclear. We have now investigated this action of pitavastatin in Dahl salt-sensitive (DS) rats. 2. The DS rats progressively develop marked hypertension when fed a diet containing 8{\%} NaCl from 7 weeks of age. These animals exhibited pronounced cardiac hypertrophy and fibrosis, as well as upregulation of fetal-type cardiac gene expression at 12 weeks of age, compared with DS rats fed a diet containing 0.3{\%} NaCl. The abundance of mRNAs for collagen types I and III, angiotensin-converting enzyme, transforming growth factor-β1 and connective tissue growth factor was also increased in the heart of rats on the high-salt diet. 3. Treatment of rats on the high-salt diet with a non-antihypertensive dose of pitavastatin (0.3 or 1 mg/kg per day) from 7 to 12 weeks of age attenuated the development of cardiac hypertrophy and fibrosis, as well as inhibiting the upregulation of cardiac gene expression. Pitavastatin also blocked the translocation of RhoA to the membrane fraction of the left ventricle and RhoA activation, as well as the phosphorylation of the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK)-1 and ERK-2 and an increase in the DNA binding activity of serum response factor (SRF) in the heart induced by the high-salt diet. 4. These findings suggest that the effects of pitavastatin on load-induced cardiac hypertrophy and fibrosis are independent of its cholesterol-lowering action and may be mediated, at least in part, through inhibition of RhoA-ERK-SRF signalling.",
author = "Masako Saka and Koji Obata and Sahoko Ichihara and Cheng, {Xian Wu} and Hirotaka Kimata and Akiko Noda and Hideo Izawa and Kohzo Nagata and Mitsuhiro Yokota",
year = "2006",
month = "12",
day = "1",
doi = "10.1111/j.1440-1681.2006.04508.x",
language = "English",
volume = "33",
pages = "1164--1171",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "12",

}

Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin : Potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway. / Saka, Masako; Obata, Koji; Ichihara, Sahoko; Cheng, Xian Wu; Kimata, Hirotaka; Noda, Akiko; Izawa, Hideo; Nagata, Kohzo; Yokota, Mitsuhiro.

:: Clinical and Experimental Pharmacology and Physiology, 巻 33, 番号 12, 01.12.2006, p. 1164-1171.

研究成果: Article

TY - JOUR

T1 - Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin

T2 - Potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway

AU - Saka, Masako

AU - Obata, Koji

AU - Ichihara, Sahoko

AU - Cheng, Xian Wu

AU - Kimata, Hirotaka

AU - Noda, Akiko

AU - Izawa, Hideo

AU - Nagata, Kohzo

AU - Yokota, Mitsuhiro

PY - 2006/12/1

Y1 - 2006/12/1

N2 - 1. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) manifest pleiotropic effects that may contribute to their therapeutic efficacy. However, the mechanism of the beneficial action of statins on cardiac hypertrophy and fibrosis remains unclear. We have now investigated this action of pitavastatin in Dahl salt-sensitive (DS) rats. 2. The DS rats progressively develop marked hypertension when fed a diet containing 8% NaCl from 7 weeks of age. These animals exhibited pronounced cardiac hypertrophy and fibrosis, as well as upregulation of fetal-type cardiac gene expression at 12 weeks of age, compared with DS rats fed a diet containing 0.3% NaCl. The abundance of mRNAs for collagen types I and III, angiotensin-converting enzyme, transforming growth factor-β1 and connective tissue growth factor was also increased in the heart of rats on the high-salt diet. 3. Treatment of rats on the high-salt diet with a non-antihypertensive dose of pitavastatin (0.3 or 1 mg/kg per day) from 7 to 12 weeks of age attenuated the development of cardiac hypertrophy and fibrosis, as well as inhibiting the upregulation of cardiac gene expression. Pitavastatin also blocked the translocation of RhoA to the membrane fraction of the left ventricle and RhoA activation, as well as the phosphorylation of the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK)-1 and ERK-2 and an increase in the DNA binding activity of serum response factor (SRF) in the heart induced by the high-salt diet. 4. These findings suggest that the effects of pitavastatin on load-induced cardiac hypertrophy and fibrosis are independent of its cholesterol-lowering action and may be mediated, at least in part, through inhibition of RhoA-ERK-SRF signalling.

AB - 1. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) manifest pleiotropic effects that may contribute to their therapeutic efficacy. However, the mechanism of the beneficial action of statins on cardiac hypertrophy and fibrosis remains unclear. We have now investigated this action of pitavastatin in Dahl salt-sensitive (DS) rats. 2. The DS rats progressively develop marked hypertension when fed a diet containing 8% NaCl from 7 weeks of age. These animals exhibited pronounced cardiac hypertrophy and fibrosis, as well as upregulation of fetal-type cardiac gene expression at 12 weeks of age, compared with DS rats fed a diet containing 0.3% NaCl. The abundance of mRNAs for collagen types I and III, angiotensin-converting enzyme, transforming growth factor-β1 and connective tissue growth factor was also increased in the heart of rats on the high-salt diet. 3. Treatment of rats on the high-salt diet with a non-antihypertensive dose of pitavastatin (0.3 or 1 mg/kg per day) from 7 to 12 weeks of age attenuated the development of cardiac hypertrophy and fibrosis, as well as inhibiting the upregulation of cardiac gene expression. Pitavastatin also blocked the translocation of RhoA to the membrane fraction of the left ventricle and RhoA activation, as well as the phosphorylation of the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK)-1 and ERK-2 and an increase in the DNA binding activity of serum response factor (SRF) in the heart induced by the high-salt diet. 4. These findings suggest that the effects of pitavastatin on load-induced cardiac hypertrophy and fibrosis are independent of its cholesterol-lowering action and may be mediated, at least in part, through inhibition of RhoA-ERK-SRF signalling.

UR - http://www.scopus.com/inward/record.url?scp=33845546752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845546752&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1681.2006.04508.x

DO - 10.1111/j.1440-1681.2006.04508.x

M3 - Article

C2 - 17184496

AN - SCOPUS:33845546752

VL - 33

SP - 1164

EP - 1171

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 12

ER -